Ascentage Pharma Group International (ASPHF)
USD 2.69
(0.0%)
USD 2.69
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 221.98 Million | 209.71 Million | 27.91 Million | 12.45 Million | 14.51 Million | 6.8 Million |
| Cost of Revenue | 30.54 Million | 21.99 Million | 3.32 Million | 1.96 Million | 2.09 Million | - |
| Gross Profit | 191.44 Million | 187.71 Million | 24.58 Million | 10.48 Million | 12.41 Million | 6.8 Million |
| Operating Expenses | 1.06 Billion | 1.03 Billion | 894.41 Million | 674.42 Million | 595.1 Million | 330.65 Million |
| Selling, General and Administrative Expenses | 376.46 Million | 328.01 Million | 110 Million | 64.05 Million | 161.64 Million | 61.49 Million |
| Research and Development Expenses | 706.97 Million | 743.1 Million | 766.49 Million | 564.57 Million | 463.88 Million | 249.56 Million |
| Other Expenses | -1.4 Million | -3.12 Million | -23.41 Million | -23.81 Million | -913.9 Million | -25.75 Million |
| Cost and Expenses | 1.09 Billion | 1.05 Billion | 897.74 Million | 676.39 Million | 597.19 Million | 330.65 Million |
| Operating Income | -838.93 Million | -846.12 Million | -876.22 Million | -665.44 Million | -1.48 Billion | -342.53 Million |
| Interest Expense | 96.05 Million | 52.78 Million | 16.73 Million | 6.25 Million | 4.27 Million | 36.91 Million |
| Income Tax Expense | -7.15 Million | -4.24 Million | -49.82 Million | 2.15 Million | -1.6 Million | -1.6 Million |
| Earnings before Tax | -932.86 Million | -887.17 Million | -832.24 Million | -675.44 Million | -1.48 Billion | -346.9 Million |
| Net Income | -925.63 Million | -882.92 Million | -782.42 Million | -677.6 Million | -1.48 Billion | -345.3 Million |
| Earnings Per Share Basic | -3.28 | -3.35 | -3.07 | -3.14 | -12.69 | -1.67 |
| Earnings Per Share Diluted | -3.28 | -3.35 | -3.07 | -3.14 | -12.69 | -1.67 |
| Weighted Average Shares Outstanding | 282.29 Million | 263.66 Million | 254.61 Million | 215.9 Million | 116.72 Million | 207.07 Million |
| Weighted Average Shares Outstanding (Diluted) | 282.29 Million | 263.66 Million | 254.61 Million | 215.9 Million | 116.72 Million | 207.07 Million |
| Gross Margin | 0.86 | 0.90 | 0.88 | 0.84 | 0.86 | 1.00 |
| EBIT Margin | -3.35 | -3.73 | -30.38 | -51.25 | -100.38 | -47.61 |
| Profit Margin | -4.17 | -4.21 | -28.03 | -54.43 | -102.03 | -50.73 |
| EBITDA | -743.61 Million | -783.2 Million | -847.9 Million | -638.02 Million | -1.45 Billion | -291.52 Million |
| Earnings Before Tax Margin | -3.78 | -4.03 | -31.39 | -53.45 | -102.20 | -50.32 |
| Breakdown | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Revenue | 221.98 Million | 5.58 Million | 5.42 Million | 9.83 Million | 10.38 Million | 209.71 Million |
| Cost of Revenue | 30.54 Million | 872.73 Thousand | 848.44 Thousand | 1.25 Million | 1.32 Million | 21.99 Million |
| Gross Profit | 191.44 Million | 4.71 Million | 4.58 Million | 8.58 Million | 9.06 Million | 187.71 Million |
| Operating Expenses | 1.06 Billion | 41.08 Million | 39.93 Million | 32.9 Million | 34.76 Million | 1.03 Billion |
| Selling, General and Administrative Expenses | - | 14.21 Million | 13.82 Million | 12.03 Million | 12.71 Million | - |
| Research and Development Expenses | - | 27.97 Million | 27.19 Million | 21.34 Million | 22.55 Million | - |
| Other Expenses | -1.4 Million | - | - | - | - | -3.12 Million |
| Cost and Expenses | 1.09 Billion | 41.95 Million | 40.78 Million | 34.15 Million | 36.08 Million | 1.05 Billion |
| Operating Income | -838.93 Million | -37.48 Million | -36.43 Million | -24.8 Million | -26.2 Million | -846.12 Million |
| Interest Expense | 96.05 Million | 5.99 Million | - | 7.6 Million | - | 52.78 Million |
| Income Tax Expense | -7.15 Million | 697.11 Thousand | 677.71 Thousand | 189.23 Thousand | 199.92 Thousand | -4.24 Million |
| Earnings before Tax | -932.86 Million | -37.56 Million | -36.51 Million | -27.53 Million | -29.09 Million | -887.17 Million |
| Net Income | -925.63 Million | -36.86 Million | -35.83 Million | -27.72 Million | -29.29 Million | -882.92 Million |
| Earnings Per Share Basic | - | -0.13 | -0.12 | -0.10 | -0.11 | - |
| Earnings Per Share Diluted | - | -0.13 | -0.12 | -0.10 | -0.11 | - |
| Weighted Average Shares Outstanding | 282.29 Million | 290.04 Million | 290.04 Million | 274.55 Million | 274.55 Million | 263.66 Million |
| Weighted Average Shares Outstanding (Diluted) | 282.29 Million | 290.04 Million | 290.04 Million | 274.55 Million | 274.55 Million | 263.66 Million |
| Gross Margin | 0.86 | 0.84 | 0.84 | 0.87 | 0.87 | 0.90 |
| EBIT Margin | - | -6.21 | -6.21 | -2.24 | -2.24 | - |
| Profit Margin | -4.17 | -6.60 | -6.60 | -2.82 | -2.82 | -4.21 |
| EBITDA | - | -34.7 Million | -33.74 Million | -22.06 Million | -23.3 Million | - |
| Earnings Before Tax Margin | -3.78 | -6.71 | -6.71 | -2.52 | -2.52 | -4.03 |
CLV
CONFIPET
VDEVF
RCI
OXIHF
5988